tbuckley/cabot-search huggingface dataset:
A Polypill Strategy to Improve Adherence
Authors: José M. Castellano, Ginés Sanz, José L. Peñalvo, Sameer Bansilal, Antonio Fernández-Ortiz, Luz Alvarez, Luis Guzmán, Juan Carlos Linares, Fernando García, Fabiana D’Aniello, Joan Albert Arnáiz, Sara Varea, Felipe Martínez, Alberto Lorenzatti, Iñaki Imaz, Luis M. Sánchez-Gómez, Maria Carla Roncaglioni, Marta Baviera, Sidney C. Smith, Kathryn Taubert, Stuart Pocock, Carlos Brotons, Michael E. Farkouh, Valentin Fuster
Journal: Journal of the American College of Cardiology (2014)
Abstract 15193: Sudden Arrhythmic Death in a Contemporary Cohort of Adults with Congenital Heart Disease
Authors: Zeliha Koyak, Louise Harris, Joris R De Groot, Candice Silversides, Berto J Bouma, Erwin N Oechslin, Werner Budts, Isabelle C Van Gelder, Barbara J Mulder
Journal: Circulation (2011)

Objectives Sudden cardiac death (SCD) is a major cause of mortality in adults with congenital heart disease (CHD). Earlier studies showed that patients with left-sided outflow lesions, tetralogy of...
Relation of psychopathology in general medical inpatients to use and cost of services
Authors: J L Levenson, R M Hamer, L F Rossiter
Journal: American Journal of Psychiatry (1990)

The authors investigated the relation between psychopathology in medically ill inpatients and use and cost of medical care services. Of 455 medical inpatients, the Medical Inpatient Screening Test identified 27.9% as very depressed, 27.5% as very anxious, 20.2% as having cognitive dysfunction, and 8.6% as having high pain levels. Overall, the test identified 51% of the patients as having high levels of psychopathology or pain. These subjects had a 40% longer median length of hospital stay and 35% greater mean hospital costs than those with low levels of psychopathology or pain. Patients with greater psychopathology also had higher hospital charges, more procedures during hospitalization, and more discharge diagnoses but did not differ from the other patients in sex, race, age, diagnosis-related group (DRG) major diagnostic category, or DRG weight.
The Application of the Air Force Physical Efficiency Tests to Men and Women.
Authors: Lucy Davis Cripps
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stenotic Aortic Valve Area
Authors: Frank A. Flachskampf
Journal: JACC. Cardiovascular imaging (2015)

In aortic stenosis, the aortic valve area (AVA) is intuitively the most appealing measure of severity because it is supposed to be (largely) independent of stroke volume and left ventricular pump function and reflects most closely “stenosis.” Calculation of the AVA by the continuity equation is
Complications of postchemotherapy residual tumor resection in patients with germ cell cancer
Authors: P. Albers, C. Bingöl, R. Witthuhn, P. de Geeter
Journal: Journal of Clinical Oncology (2009)

e16077 Background: Residual tumor resection (RTR) is mandatory in all patients with advanced germ cell tumors and visible residual disease after chemotherapy. Full bilateral RTR is the proposed standard of care. However, in lately published series, the rate of nerve-sparing procedures was only 40%. Stage-related RTR may decrease surgical complications, enhance the rate of postoperative antegrade ejaculations and may not compromise oncological efficacy. Methods: A retrospective analysis of 98 patients in a tertial referral center with RTR (2003–2008) was performed using the RTR database and patients´ charts to correlate the extent of surgery to complications and outcome. Results: 49% of patients initially had IGCCCG intermediate and poor prognosis features. In 34%, residual tumor diameter was &gt;5 cm. With a median age of 33 yrs (17–65), the median time of surgery was 210 min (90–604) with a median blood loss of 500 cc (50–5000). In 25 of 98 patients a full bilateral RTR was necessary to remove all residual tumors. The median residual tumor diameter in patients with full bilateral RTR without nerve-sparing was 10.9 cm (1.5–30) as opposed to 4.3 cm (0.5–20) in patients with modified template and/or nerve-sparing approaches (not significant). In 10 pts a nephrectomy and in 9 pts a resection of the vena cava was necessary. Only 2 of each had a bilateral RTR. All CTCAE grade III/VI complications like intraoperative hemorrhage (n=25, 11/25 bilateral RTR), postoperative lymphocele (n=8, 6/8 bilateral RTR), and retrograde ejaculation (15% with modified template and/or nerve-sparing, 100% with bilateral RTR) were significantly correlated with the residual tumor size and with the field of resection. Four patients relapsed, one had an in-field relapse after a template resection. One patient died due to a postoperative aorto-duodenal fistula. Conclusions: The complication rate of RTR is strongly related to the median residual tumor size and the extent of surgery. A full bilateral resection in all patients may result in unnecessary complications in a considerable cohort of patients. The field of resection should be adapted to the primary localization of disease and full bilateral resections should be performed only in patients with bilateral disease. No significant financial relationships to disclose.
Predictors of Non-Pulmonary Vein Ectopic Beats Initiating Paroxysmal Atrial Fibrillation
Authors: Shih-Huang Lee, Ching-Tai Tai, Ming-Hsiung Hsieh, Hsuan-Ming Tsao, Yenn-Jiang Lin, Shih-Lin Chang, Jin-Long Huang, Kun-Tai Lee, Yi-Jen Chen, Jun-Jack Cheng, Shih-Ann Chen
Journal: Journal of the American College of Cardiology (2005)
Abstract 3758: Preventive Effects of Heregulin-Beta1 on Macrophage Foam Cell Formation and Atherosclerosis
Authors: Takuya Watanabe, Yoshitaka Iso, Shinji Koba, Tetsuo Sakai, Gang Xu, Shigeko Arita, Shigeki Hongo, Tsutomu Hirano, Youichi Kobayashi, Akira Miyazaki
Journal: Circulation (2008)

Human heregulins, neuregulin-1 type I polypeptides known to activate proliferation, differentiation, and survival of glial cells, neurons, and myocytes, were recently found to be expressed in macrophage foam cells within human coronary atherosclerotic lesions. Macrophage foam cell formation, characterized by cholesterol ester (CE) accumulation, is modulated by scavenger receptor class A (SR-A), acyl-CoA:cholesterol acyltransferase-1 (ACAT1), and ATP-binding cassette transporter A1 (ABCA1). The present study clarified the functional roles of heregulins in macrophage foam cell formation and atherosclerosis. Plasma heregulin-beta1 levels were significantly decreased in 31 patients with acute coronary syndrome (ACS) and 33 patients with stable angina pectoris as compared with 34 mild hypertensive patients and 40 healthy volunteers (1.3+/−0.3, 2.0+/−0.4 versus 7.6+/−1.4, 8.2+/−1.2 ng/mL; at least P &lt; 0.01). Immunoreactive heregulins and these receptor c-erbB3 were detectable within human coronary atherothrombosis obtained from ACS patients. In primary cultured human monocyte-macrophages, the expression of endogenous heregulins, heregulin-beta1, and c-erbB3 increased during monocytic differentiation into macrophages. In human macrophages differentiated by 7-day culture, exogenous heregulin-beta1, but not heregulin-alpha, significantly reduced acetylated low-density lipoprotein (acLDL)-induced CE accumulation by reducing SR-A and ACAT1 expression and by increasing ABCA1 expression at both mRNA and protein levels. Heregulin-beta1 significantly decreased endocytic uptake of [ 125 I]acLDL and increased cholesterol efflux by apolipoprotein A1 from human macrophages. Chronic infusion of heregulin-beta1 by osmotic mini-pumps into apolipoprotein E-deficient mice significantly suppressed the progression of macrophage-driven atherosclerotic lesions by 64%. Our study provides the first evidence that heregulin-beta1 may participate in anti-atherogenesis by suppressing macrophage foam cell formation via SR-A and ACAT1 down-regulation and ABCA1 up-regulation.
Rhinovirus infection interferes with induction of tolerance to aeroantigens through OX40 ligand, thymic stromal lymphopoietin, and IL-33
Authors: Amit K. Mehta, Wei Duan, Astrid M. Doerner, Suzanne L. Traves, David H. Broide, David Proud, Bruce L. Zuraw, Michael Croft
Journal: Journal of Allergy and Clinical Immunology (2015)
Correlation of cognitive symptoms with cognitive performance among brain cancer patients after radiation therapy.
Authors: S. R. Rapp, L. D. Case, M. E. Loghin, C. A. Meyers, T. J. Saphner, B. G. Sleckman, V. W. Stieber, J. N. Atkins, J. K. Giguere, E. G. Shaw
Journal: Journal of Clinical Oncology (2010)

2084 Background: Cognitive symptoms can occur among cancer patients, though the incidence and severity vary across cancer type, location, treatment and time. Some have argued that subjective cognitive symptoms reflect patients' mood or fatigue more than objective cognitive functioning per se and there are studies showing no correlation between complaints and performance. Methods: The present study describes the correlations at baseline between subjective cognitive symptoms (FACT-Brain symptoms subscale), fatigue (FACT-Fatigue) and mood (Profile of Mood States) and objective cognitive performance (Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, Digit Span Test, Trail Making Test, Grooved Pegboard and summary Cognitive Composite Score [CCS]), among 82 brain cancer survivors who are ≥ 6 months post partial or whole brain irradiation participating in a phase III clinical trial of an acetylcholinesterase inhibitor, donepezil. Results: The sample (mean age = 52 yrs.; 50% female; 83% > HS) had primary (n = 52, 63%) and metastatic (n = 30, 37%) brain tumors. Significant bivariate correlations between the FACT-Br and the CCS (r = 0.42, p < 0.0001) and 7 of 10 cognitive tests (range:-0.26 to 0.44, p < 0.05) indicate that more symptoms predicted poorer performance. Neither overall fatigue (r = 0.19, p = 0.08) nor distressed mood (r = -0.05, p = 0.67) was associated with CCS. Adjusting for tumor type (primary vs. metastatic), age, education, fatigue, QOL, sex and race revealed a very similar pattern. Conclusions: Among 6+ month survivors of brain irradiation, there is an association between objective cognitive performance and subjective cognitive symptoms while mood and fatigue are minimally related to performance. Self-reported cognitive problems are not a substitute for cognitive performance measures, however they can be a valid and useful indicator of well-being and used as a clinical outcome in this population. This study was supported by Eisai, Inc., and NIH grants NCI/DCP 2 U10 CA 81851-09-13 and NINR 5R01NR009675. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eisai Pfizer Eisai Eisai, Pfizer
Big Spring: The Casual Biography of a Prairie Town
Authors: Shine Philips
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3261: Papillary Fibroelastomas in Hypertrophic Cardiomyopathy
Authors: Gautam Kumar, Ryan J MacDonald, Paul Sorajja, William D Edwards, Steve R Ommen, Kyle W Klarich
Journal: Circulation (2007)

Introduction: Papillary fibroelastomas (PFEs) are the 3rd most common primary cardiac tumors with a prevalence of around 0.01% in patients with echocardiograms. The pathogenesis is controversial but endocardial trauma has been implicated. We hypothesized that increased turbulence in hypertrophic cardiomyopathy (HCM) would be a risk factor for PFE development and characterized PFEs in HCM. Around 5% of HCM patients had neurologic events. We postulated that patients with both PFE and HCM had a higher risk of neurologic events. Methods: We reviewed pathology records from 1990 –2006 and identified 129 subjects with PFEs and 2479 patients with HCM. We then identified the subjects who had both HCM and PFE (n = 19). All subjects signed release for use of their medical records for research. Results: 19 subjects (68.4% female) had both HCM and PFE. Mean age at diagnosis of HCM was 49 (range 21– 81) years. All had outflow tract obstruction with resting gradient &gt;/=30 mm Hg except 2 who had resting gradients &lt;30 mm Hg but elevated gradients on provocation. PFE diagnosis was after a mean of 9.7 years (SD 8.3) following HCM diagnosis. 5 subjects were diagnosed pre-operatively by transthoracic echocardiography, 2 subjects by transesophageal echocardiography and 12 subjects at surgery only. Most subjects had only 1 PFE (57.9%) but 1 subject had as many as 40 tumors. Most PFEs were on the aortic valve (47.4%) and the left ventricular side of the septum and left ventricular outflow tract (42.1%). Only 2 patients had right heart lesions that were presumably unrelated to HCM. 3 patients had previous septal myectomies and all 3 had PFEs near the previous resection. 5 of 19 subjects (26.3%) with PFE and HCM had neurologic events (either strokes or transient ischemic attacks) compared to 199 of 2261 subjects (8.8%) with HCM alone (OR = 4.1; 95% CI 1.4 –11.4, p &lt; 0.05). Conclusion: Nearly 90% of PFEs in HCM are located in the septum, left ventricular outflow tract and aortic valve. This may be supportive of endocardial trauma as a risk factor for PFE development in HCM. About a quarter of patients with PFEs and HCM had neurologic events. This may indicate that these lesions are not innocuous and should perhaps be actively searched for in patients with HCM and unexplained neurologic events.
A Text-Book of Ophthalmology.
Authors: Kenneth W. Wright
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Useful Drugs: A Selected List of Essential Drugs with Brief Discussions of Their Actions, Uses and Dosage.
Authors: Austin Edward Smith
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases
Authors: Sabine Jeromin, Christiane Eder, Sandra Weissmann, Manja Meggendorfer, Tamara Alpermann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Susanne Schnittger
Journal: Blood (2013)
Assessing Development Assistance for Mental Health in Developing Countries: 2007–2013
Authors: Barnabas J. Gilbert, Vikram Patel, Paul E. Farmer, Chunling Lu
Journal: PLoS Medicine (2015)

The Need for Investment in Global Mental Health Mental and substance-use disorders account for approximately 8% of the global burden of disease, afflicting as many as 700 million people worldwide [1,2].The most recent estimates rank Summary Points• Mental disorders are a leading cause of the global burden of disease, and the provision of mental health services in developing countries remains very limited and far from equitable.• Using the Creditor Reporting System, we estimate the amounts and patterns of development assistance for global mental health (DAMH) between 2007 and 2013.This allows us to examine how well international donors have responded to calls by global mental health advocates to scale up evidence-based services.• Although DAMH did increase between 2007 and 2013, it remains low both in absolute terms and as a proportion of total development assistance for health (DAH).The average annual DAMH between 2007 and 2013 was US$133.57million, and the proportion of DAH attributed to mental health is less than 1%.
Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF- β2 inhibitor AP 12009
Authors: H. Oettle, T. Seufferlein, R. Schmid, T. Luger, S. Ludwig, S. Schmaus, G. Wuerth, H. Heinrichs, K. Schlingensiepen
Journal: Journal of Clinical Oncology (2007)

4607 Background: TGF-β2 plays a pivotal role in tumor progression as it regulates key mechanisms, namely immunosuppression, metastasis, angiogenesis, and proliferation. The TGF-β2 inhibitor AP 12009 has shown clinical efficacy including complete and long-lasting remissions in patients with high-grade glioma. Methods: The currently ongoing clinical phase I/II study AP 12009-P001 is an open-label, multicenter, dose-escalation study. AP 12009 is being administered intravenously in adult patients with pancreatic carcinoma (PC, stage IVA/IVB), metastatic melanoma (MM, stage III/IV), or advanced colorectal carcinoma (CRC, stage III/IV). Primary endpoint is determination of the maximum tolerated dose (MTD). 3 to 6 patients per cohort (dose group) were enrolled into this dose escalation study. Results: So far, 17 patients have been treated in four dose groups, 11 patients with PC, 2 with MM, and 4 with CRC. Per cycle, AP 12009 was applied as a continuous i.v. infusion at weekly intervals in an out-patient setting. The 17 patients received one to ten cycles of AP 12009 (mean: 2.8). At the current stage, no (possibly) drug related serious adverse event (SAE), and only 17 (possibly) drug related adverse events (AEs) in eight patients have been observed. The 17 patients received one to ten cycles of AP 12009. Three dose-limiting toxicities (DLTs) occurred in the 4th dose group (exanthema grade 3 in one patient, thrombocytopenia grade 3 in two patients) and consequently, the MTD was determined as being 160 mg/m 2 /day with the current administration schedule. One patient suffering from MM stage IV is still alive 64 weeks after start of treatment. Moreover, one PC patient (stage IV) from the 2nd cohort is still after 72 weeks, having experienced a complete response. Further dose escalation studies in PC, MM, and CRC patients using a modified schedule are currently in preparation. Conclusions: In conclusion, encouraging case reports from the phase I/II study along with a good safety profile form a rational basis for the use of the TGF-β2 inhibitor AP 12009 as targeted therapy for advanced solid tumors such as PC, MM and CRC. No significant financial relationships to disclose.
Municipal Sanitation in the United States.
Authors: Charles Value Chapin
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal